Pharmacy

Insys Therapeutics, the troubled fentanyl spray maker, has replaced its CEO.

The U.S. Supreme Court declined to hear Allergan's appeal defending its effort to shield its patents from review by selling them to a Native American tribe, according to STAT. The rebuff leaves a lower court ruling in place.

CVS Health will pay $535,000 to resolve allegations that some of its pharmacies in Rhode Island filled dozens of forged prescriptions, according to local TV broadcaster WPRI.

Rutland Pharmacy, an independent pharmacy in Vermont, is suing a New York insurer, MVP Health Care, for pushing its customers to use a mail order pharmacy to fill prescriptions, according to the Burlington Free Press. 

Achaogen, a biopharmaceutical company based in South San Francisco, Calif., filed for Chapter 11 bankruptcy April 15.

Nationwide Children's Hospital in Columbus, Ohio, has quietly become a go-to hub for gene therapy research and production, according to Xconomy National.

As disruptors continue to push into the healthcare arena and pressure builds to cut drug prices, pharmaceutical companies are taking steps to remain competitive and enhance their drug pipelines.

Parents who lost children to the opioid epidemic are pressing Harvard University to strip the Sackler name from one of its museums, according to The Boston Globe.

Duluth, Minn.-based Essentia Health will take over ownership of two pharmacies in Minnesota in June, according to The Brainerd Dispatch.

Contract drug manufacturer Catalent will buy Paragon Bioservices, a privately held company focused on gene therapy production, for $1.2 billion, according to The Wall Street Journal.